By Research Phase
Efficient, high-quality and cost-effective services meet and exceed customer expectations
For pharmaceutical and biotech companies, it is vital to find out which drug candidates are worth investing in for research and development as quickly as possible. Ideally this should happen before the costly preclinical trials begin. Based on over 20 years s experience in candidate selection, JOINN integrated a suite of advanced screening technologies to provide drug discovery support for clients. Our screening services include efficiency screening (in vivo/in vitro), bioavailability, ADME screening, and Non-GLP Toxicology studies.
JOINN has built a thorough quality management system complied with the international standard: CNAS/ILAC-MRA certification, NMPA, US FDA, OECD and Korean MFDS GLP certification and international AAALAC accreditation. JOINN can provide customized services tailored to client’s specific needs for non-clinical safety assessments, clinical trials, registrations, and pharmacovigilance which cover the entire spectrum from development to final drug registration. JOINN also provides services in animal feed and veterinary medicine evaluation, pesticide evaluation, medical device evaluations, etc
JOINN focus on early stage clinical research which could provide phase I clinical center, clinical trials (CRO) and sample analysis services.
JOINN is a third-party testing laboratory for drug quality research and verification of protein drugs, vaccines, gene and cell therapy products, etc., providing the society with innovative drug quality standard research, verification method establishment, preparation and identification of standard substances, cell bank, bacteria and virus seed bank, stock solution and finished product testing. Production process quality control key steps such as virus inactivation and clearance verification. According to the requirements of quality evaluation of innovative drug application, new methods, new technologies and new standards were established to meet the constantly emerging demands for quality research and testing of biological drugs, and to support and promote the development and industrialization of innovative drugs.